KalVista appoints Benjamin Palleiko as CEO; Crockett resigns in planned transition

KalVista Pharmaceuticals, Inc.

T. Andrew Crockett resigned as CEO and board director effective March 6, 2024, not due to any disagreement.
Benjamin L. Palleiko appointed CEO and to the Board; he was President/CBO/CFO and remains principal financial officer.
Palleiko receives base salary of $661,800/year, 60% bonus target, and 250,000 RSUs vesting quarterly over 4 years.
Crockett separation includes 18 months base salary lump sum, full FY2024 target bonus, and 150,000 RSU/PSU acceleration.
Sebetralstat NDA filing on track for H1 2024 in US; Europe and Japan filings in H2 2024 after positive Phase 3 trial.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

T. Andrew Crockett

Chief Executive Officer

KALV · KalVista Pharmaceuticals, Inc.

Effective: 2024-03-06
Successor: Benjamin L. Palleiko
Filed: March 7, 2024, 6:59 PM ET

On March 6, 2024, T. Andrew Crockett announced his resignation from his position as the Chief Executive Officer and from his position on the Board, effective immediately.

Appointed

Benjamin L. Palleiko

Chief Executive Officer

KALV · KalVista Pharmaceuticals, Inc.

Effective: 2024-03-06
Filed: March 7, 2024, 6:59 PM ET

Effective March 6, 2023, the Board of Directors (the “ Board ”) of KalVista Pharmaceuticals, Inc. (the “ Company ”) appointed Benjamin L. Palleiko, the Company’s President, Chief Business Officer and Chief Financial Officer, as its Chief Executive Officer and principal executive officer and he will remain the principal financial officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

T. Andrew Crockett resigned as Chief Executive Officer at KalVista Pharmaceuticals, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On March 6, 2024, T. Andrew Crockett announced his resignation from his position as the Chief Executive Officer and from his position on the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Benjamin L. Palleiko was appointed as Chief Executive Officer at KalVista Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Effective March 6, 2023, the Board of Directors (the “ Board ”) of KalVista Pharmaceuticals, Inc. (the “ Company ”) appointed Benjamin L. Palleiko, the Company’s President, Chief Business Officer and Chief Financial Officer, as its Chief Executive Officer and principal executive officer and he will remain the principal financial officer.

View on SEC.gov

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-061344

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.